• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

罕见病医疗保健是否受益于立法改革?

[Does the healthcare for rare diseases benefit from the legislative reforms?].

作者信息

Heyder Ralf

机构信息

Verband der Universitätsklinika Deutschlands e. V., Alt-Moabit 96, 10559, Berlin, Deutschland.

出版信息

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):487-493. doi: 10.1007/s00103-017-2528-7.

DOI:10.1007/s00103-017-2528-7
PMID:28289779
Abstract

BACKGROUND

The founding of the National Action League for People with Rare Diseases (NAMSE) in 2010 represents the creation of a significant political platform. In addition, recent years had seen Germany and the EU adopt specific legislative measures aimed at improving healthcare for people with rare diseases.

OBJECTIVE

In this article we will give an overview of the legislative reforms adopted between 2013 and 2016 and evaluate how the specific healthcare situation of people with rare diseases has been improved.

MATERIALS AND METHODS USED

This article analyzes the health care legislative reforms adopted during the 18th term (since 2013) of the German lower house, the Bundestag, as well as their self-governing implementation. The analysis also extends to similar political initiatives of the European Commission.

RESULTS

The impact of the recent hospital reforms on the health care received by patients or on the work of health care providers in the field of rare diseases cannot be assessed conclusively at this point (January 2017). One positive feature is that the health care coverage mandate of the university hospital outpatient departments now also comprises rare diseases.

DISCUSSION

Recent legislative measures have created possibilities to improve the economic position of centers for rare diseases and university hospital outpatient departments. What these improvements will look like specifically depends on the implementation within the hospital plans of the federal states as well as on the outcome of the remuneration negotiations between university hospitals and health insurance funds.

摘要

背景

2010年全国罕见病患者行动联盟(NAMSE)的成立标志着一个重要政治平台的创建。此外,近年来德国和欧盟采取了旨在改善罕见病患者医疗保健的具体立法措施。

目的

在本文中,我们将概述2013年至2016年期间通过的立法改革,并评估罕见病患者的具体医疗状况是如何得到改善的。

使用的材料和方法

本文分析了德国下议院联邦议院第18届任期(自2013年起)期间通过的医疗保健立法改革及其自治实施情况。分析还扩展到欧盟委员会的类似政治举措。

结果

目前(2017年1月)尚无法最终评估近期医院改革对患者所接受医疗保健或罕见病领域医疗服务提供者工作的影响。一个积极的方面是,大学医院门诊部的医疗保健覆盖任务现在也包括罕见病。

讨论

近期的立法措施为改善罕见病中心和大学医院门诊部的经济状况创造了可能性。这些改善具体会是什么样子取决于联邦州医院计划中的实施情况以及大学医院与健康保险基金之间薪酬谈判的结果。

相似文献

1
[Does the healthcare for rare diseases benefit from the legislative reforms?].罕见病医疗保健是否受益于立法改革?
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):487-493. doi: 10.1007/s00103-017-2528-7.
2
[Seven years of the National Action League for People with Rare Diseases : NAMSE - a success story?!].[罕见病患者全国行动联盟成立七周年:NAMSE——一个成功故事?!]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):479-486. doi: 10.1007/s00103-017-2530-0.
3
[Measures to improve the health situation of patients with rare diseases in Germany. A comparison with the National Action Plan].[德国改善罕见病患者健康状况的措施。与国家行动计划的比较]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Oct;57(10):1216-23. doi: 10.1007/s00103-014-2040-2.
4
[Rare diseases, digitization, and the National Action League for People with Rare Diseases (NAMSE)].[罕见病、数字化与全国罕见病患者行动联盟(NAMSE)]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Nov;65(11):1119-1125. doi: 10.1007/s00103-022-03597-w. Epub 2022 Oct 14.
5
[European Reference Networks : Consequences for healthcare in Germany].[欧洲参考网络:对德国医疗保健的影响]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):537-541. doi: 10.1007/s00103-017-2533-x.
6
[Evaluation of external quality assurance in accordance with sect. 137 SGB V at the Carl Gustav Carus university hospital in Dresden].[德累斯顿卡尔·古斯塔夫·卡鲁斯大学医院依据《社会法典》第五卷第137条进行的外部质量保证评估]
Z Evid Fortbild Qual Gesundhwes. 2013;107(8):541-7. doi: 10.1016/j.zefq.2013.08.011. Epub 2013 Oct 8.
7
[Quality of German medical services: a review].[德国医疗服务质量:综述]
Z Rheumatol. 2016 Feb;75(1):97-102. doi: 10.1007/s00393-015-0021-y.
8
[Quality management from the viewpoint of the Federal Public Health Ministry].[从联邦公共卫生部的视角看质量管理]
Herz. 1996 Oct;21(5):299-303.
9
[Clinical performance measurement in surgery and orthopedics -- new aspects in 2004].[外科与骨科的临床绩效评估——2004年的新进展]
Zentralbl Chir. 2004 Jun;129(3):165-71. doi: 10.1055/s-2004-822739.
10
[Overview, analysis and evaluation of the 1995 public health structural law and the federal social care law from the viewpoint of the trauma surgery department of a university clinic. Measures for preparation of a new reimbursement system and documentation requirements].[从大学诊所创伤外科的角度对1995年公共卫生结构法和联邦社会护理法进行概述、分析与评估。新报销系统的准备措施及文件要求]
Unfallchirurg. 1995 Nov;98(11):592-607.

引用本文的文献

1
Living with a rare disease - experiences and needs in pediatric patients and their parents.与罕见病共存——儿科患者及其父母的经历和需求。
Orphanet J Rare Dis. 2023 Aug 11;18(1):242. doi: 10.1186/s13023-023-02837-9.
2
[Sustainable reimbursement of the B‑centres for rare diseases in Germany-status quo and solution approaches].[德国罕见病B中心的可持续报销——现状与解决方法]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Sep;65(9):872-880. doi: 10.1007/s00103-022-03562-7. Epub 2022 Jul 21.